全文获取类型
收费全文 | 25679篇 |
免费 | 1806篇 |
国内免费 | 138篇 |
专业分类
耳鼻咽喉 | 90篇 |
儿科学 | 1483篇 |
妇产科学 | 604篇 |
基础医学 | 2211篇 |
口腔科学 | 110篇 |
临床医学 | 2497篇 |
内科学 | 7836篇 |
皮肤病学 | 462篇 |
神经病学 | 2006篇 |
特种医学 | 224篇 |
外科学 | 2945篇 |
综合类 | 606篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 2222篇 |
眼科学 | 954篇 |
药学 | 1115篇 |
2篇 | |
中国医学 | 50篇 |
肿瘤学 | 2199篇 |
出版年
2024年 | 41篇 |
2023年 | 247篇 |
2022年 | 229篇 |
2021年 | 346篇 |
2020年 | 338篇 |
2019年 | 119篇 |
2018年 | 466篇 |
2017年 | 495篇 |
2016年 | 550篇 |
2015年 | 534篇 |
2014年 | 445篇 |
2013年 | 709篇 |
2012年 | 1993篇 |
2011年 | 2270篇 |
2010年 | 795篇 |
2009年 | 772篇 |
2008年 | 2434篇 |
2007年 | 2314篇 |
2006年 | 2001篇 |
2005年 | 2088篇 |
2004年 | 2042篇 |
2003年 | 2079篇 |
2002年 | 1673篇 |
2001年 | 1249篇 |
2000年 | 282篇 |
1999年 | 137篇 |
1998年 | 199篇 |
1997年 | 116篇 |
1996年 | 90篇 |
1995年 | 57篇 |
1994年 | 71篇 |
1993年 | 36篇 |
1992年 | 41篇 |
1991年 | 32篇 |
1990年 | 37篇 |
1989年 | 36篇 |
1988年 | 36篇 |
1987年 | 38篇 |
1986年 | 33篇 |
1985年 | 24篇 |
1984年 | 24篇 |
1983年 | 11篇 |
1982年 | 17篇 |
1981年 | 19篇 |
1980年 | 12篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1974年 | 4篇 |
1973年 | 3篇 |
1970年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Randomized,comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial 总被引:11,自引:0,他引:11
Panitch H Goodin DS Francis G Chang P Coyle PK O'Connor P Monaghan E Li D Weinshenker B;EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy;University of British Columbia MS/MRI Research Group 《Neurology》2002,59(10):1496-1506
BACKGROUND: Interferon beta (IFNbeta) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects on disability. The most effective dose regimen remains controversial. METHODS: This randomized, controlled, multicenter trial compared the efficacy and safety of IFNbeta-1a (Rebif) 44 micro g subcutaneously three times weekly (tiw), and IFNbeta-1a (Avonex) 30 micro g IM once weekly (qw) in 677 patients with RRMS. Assessors blinded to treatment performed neurologic and MRI evaluations. The primary endpoint was the proportion of patients who were relapse free at 24 weeks; the principal MRI endpoint was the number of active lesions per patient per scan at 24 weeks. RESULTS: After 24 weeks, 74.9% (254/339) of patients receiving IFNbeta-1a 44 micro g tiw remained relapse free compared with 63.3% (214/338) of those given 30 micro g qw. The odds ratio for remaining relapse free was 1.9 (95% CI, 1.3 to 2.6; p = 0.0005) at 24 weeks and 1.5 (95% CI, 1.1 to 2.1; p = 0.009) at 48 weeks, favoring 44 micro g tiw. Patients receiving 44 micro g tiw had fewer active MRI lesions (p < 0.001 at 24 and 48 weeks) compared with those receiving 30 micro g qw. Injection-site reactions were more frequent with 44 micro g tiw (83% vs 28%, p < 0.001), as were asymptomatic abnormalities of liver enzymes (18% vs 9%, p = 0.002) and altered leukocyte counts (11% vs 5%, p = 0.003) compared with the 30 micro g qw dosage. Neutralizing antibodies developed in 25% of 44 micro g tiw patients and in 2% of patients receiving 30 micro g qw. CONCLUSIONS: IFNbeta-1a 44 micro g subcutaneously tiw was more effective than IFNbeta-1a 30 micro g IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment. 相似文献
992.
993.
994.
The performance of two rapid quantitative D-dimer assays in 287 patients with clinically suspected pulmonary embolism 总被引:5,自引:0,他引:5
de Monyé W Sanson BJ Büller HR Pattynama PM Huisman MV;ANTELOPE Study Group 《Thrombosis research》2002,107(6):283-286
Context: Objective tests are necessary for the diagnosis of pulmonary embolism (PE). D-dimer assays have been suggested as useful screening tests to exclude this diagnosis. Objective: To compare the diagnostic accuracy of two rapid quantitative D-dimers in patients with suspected pulmonary embolism. Design: Plasma D-dimer levels were measured using two commercially available assays (Tinaquant® and Vidas®). A strict imaging protocol was used to arrive at a final diagnosis of PE or deep venous thrombosis (DVT). Setting: Multicenter study in six Dutch referral centers. Patients: A total of 287 in- and outpatients with clinically suspected pulmonary embolism. Main outcome measures: Diagnostic accuracy indices for the two assays were calculated and additional receiver-operated characteristics (ROC) analysis was performed. Results: Using the manufacturer's advised cutoff values, the sensitivity and specificity were 88% and 52% for Vidas and 82% and 61% for Tinaquant, respectively. These differences were statistically significant (McNemar, P<0.0001). However, no statistical differences were found between the two assays using ROC analysis (AUC=0.78 for both assays). Conclusions: Both quantitative D-dimer tests had similar diagnostic accuracy; however, at the manufacturer's advised cutoff level, Vidas performed significantly better. Nevertheless, to safely exclude pulmonary embolism, D-dimer assays should be combined with other diagnostic tests. 相似文献
995.
Wolfe GI Barohn RJ Foster BM Jackson CE Kissel JT Day JW Thornton CA Nations SP Bryan WW Amato AA Freimer ML Parry GJ;Myasthenia Gravis-IVIG Study Group 《Muscle & nerve》2002,26(4):549-552
We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed. 相似文献
996.
D'Alfonso S Mellai M Giordano M Pastore A Malferrari G Naldi P Repice A Liguori M Cannoni S Milanese C Caputo D Savettieri G Momigliano-Richiardi P;Italian Group for the Study of Multiple Sclerosis Genetics 《Journal of neuroimmunology》2002,126(1-2):196-204
The myelin-associated glycoprotein (MAG) gene is an appealing candidate in the 19q13 Multiple Sclerosis (MS) candidate region. Using denaturing high performance liquid chromatography (DHPLC), we identified 14 single nucleotide polymorphisms (SNPs) in MAG coding and regulatory regions, and we tested their possible association with MS in Italian patient and control DNA pools. Eight variations had a frequency <0.05, i.e. below the detection limit in the pools. Of these, Arg537Cys was further studied with individually genotyped individuals and was detected in 1/189 patients and 0/85 controls. The frequency of the six remaining SNPs were not significantly different in pools including a total of 1266 patient and 1612 control chromosomes. Considering the statistical power of the experimental design, these results exclude the MAG gene as an MS susceptibility factor with an odds ratio (OR) equal or higher than 1.3. 相似文献
997.
998.
999.
1000.
Roberts DL Anstey AV Barlow RJ Cox NH Newton Bishop JA Corrie PG Evans J Gore ME Hall PN Kirkham N;British Association of Dermatologists;Melanoma Study Group 《The British journal of dermatology》2002,146(1):7-17
These guidelines for management of cutaneous melanoma present evidence-based guidance for treatment, with identification of the strength of evidence available at the time of preparation of the guidelines, and a brief overview of epidemiological aspects, diagnosis and investigation. To reflect the collaborative process for the U.K., they are subject to dual publication in the British Journal of Dermatology and the British Journal of Plastic Surgery. 相似文献